Ipsen completes purchase of consumer healthcare products from Sanofi

Ipsen has completed its previously-announced acquisition of five consumer healthcare products from Sanofi.

The 83 million euro (70.18 million pounds) deal is intended to facilitate Ipsen's transition towards a combined prescription/over-the-counter (OTx) business model, and will leverage the company's primary care infrastructure.

The most significant product in the portfolio is Prontalgine, an analgesic for the treatment of moderate to severe pain, which is sold exclusively in France. The deal also includes the antispasmodic therapy Buscopan, the laxative Suppositoria Glycerini, and the cough and flu expectorants Mucothiol and Mucodyne.

The company said: "This transaction strengthens the evolution of Ipsen's consumer healthcare portfolio in France and central Europe, with the strategic intent to further develop the OTx model in most geographies."

Ipsen and Sanofi agreed to this transaction in February as part of the European Commission's requirement for Sanofi to divest certain assets following its purchase of the consumer healthcare division of Boehringer Ingelheim.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.